1. Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products. CPMP working party on efficacy of medicinal products note for guidance III/3630/92-EN
2. European Commission. 2009. “A Guideline on Summary of Product Characteristics”. Available athttp://www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000267.jsp&mid=WC0b01ac05800b378b
3. European Medicines Agency. 1996. “Note for Guidance on Good Clinical Practice”. ICH Topic E6 (R1). Available athttp://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf
4. European Medicines Agency. 2001. “Points to Consider on Application With 1. Meta-analyses; 2. One Pivotal Study”. CPMP/EWP/2330/99. Available athttp://www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000366.jsp&mid=WC0b01ac0580032ec4
5. European Medicines Agency. 2002. “Points to Consider on Multiplicity Issues in Clinical Trials”. CPMP/EWP/908/99, Available athttp://www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000366.jsp&mid=WC0b01ac0580032ec4